PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adrenocortical carcinoma (a rare cancer of the adrenal gland).
- Your cancer is advanced and cannot be removed by surgery, and you have not yet received standard first-line treatment.
- You are between 18 and 70 years old.
- You are in generally good health (able to perform daily activities without help).
- You have at least one measurable tumor (visible on scans).
- Your blood counts, liver, kidney, and heart function are within acceptable ranges (confirmed by tests).
- You are willing to use effective contraception (if applicable) during the study and for several months after.
- You do not have a history of other cancer within the past 5 years (except some cured skin or thyroid cancers).
- You have not had certain prior treatments (immunotherapy, TKI drugs, or other experimental drugs) in the recent past.
- You do not have active infections, autoimmune diseases, or uncontrolled health conditions like high blood pressure or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
This trial tests two targeted drugs, anlotinib and benmelstobart, for people with advanced pheochromocytoma or paraganglioma that has spread or come back after treatment. These drugs may help shrink tumors or slow their growth.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
Hear when a new Adrenal Cortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.